

References for Products 36340 and 36341

1. Cases-Gonzalez CE, Franco S, Martinez MA, Menendez-Arias L. (2007) Mutational Patterns Associated with the 69 Insertion Complex in Multi-drug-resistant HIV-1 Reverse Transcriptase that Confer Increased Excision Activity and High-level Resistance to Zidovudine. *J Mol Biol*, 365, 298.
2. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. (2007) A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. *Cancer Chemother Pharmacol*, 59, 79.
3. Adams M, Efferth T, Bauer R. (2006) Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from *Artemisia argyi*. *Planta Med*, 72, 862.
4. Annese V, Latiano A, Rossi L, Bossa F, Damonte G, Dallapiccola B, Serafini S, Pierige F, Andriulli A, Magnani M. (2006) The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. *Eur Rev Med Pharmacol Sci*, 10, 27.
5. Best B, Haubrich R. (2006) Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. *Expert Opin Investig Drugs*, 15, 59.
6. Biancofiore G, Tascini C, Bisa M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F. (2006) Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant *Acinetobacter baumannii* multifocal infection. *Minerva Anestesiol*.
7. Brouwer CP, Bogaards SJ, Wulferink M, Velders MP, Welling MM. (2006) Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) *Staphylococcus aureus* in mice. *Peptides*, 27, 2585.
8. Carta A, Loriga M, Piras S, Paglietti G, La Colla P, Busonera B, Collu G, Loddo R. (2006) Synthesis of variously substituted 3-phenoxyethyl quinoxalin-2-ones and quinoxalines capable to potentiate in vitro the antiproliferative activity of anticancer drugs in multi-drug resistant cell lines. *Med Chem*, 2, 113.
9. Chen SH, Yang CP, Chiu CH, Chia JH, Huang IA, Jaing TH. (2006) Fulminant septicaemia caused by multi-drug-resistant *Streptococcus mitis* following unrelated cord blood transplantation. *Ann Trop Paediatr*, 26, 247.
10. Cobbold RN, Rice DH, Davis MA, Besser TE, Hancock DD. (2006) Long-term persistence of multi-drug-resistant *Salmonella enterica* serovar Newport in two dairy herds. *J Am Vet Med Assoc*, 228, 585.
11. Engchanil C, Kosalaraksa P, Lulitanond V, Lumbiganon P, Chanratita W. (2006) Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs). *J Med Assoc Thai*, 89, 1713.
12. Falagas ME, Kopterides P. (2006) Risk factors for the isolation of multi-drug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*: a systematic review of the literature. *J Hosp Infect*, 64, 7.
13. Garcia Garmendia JL, Amigo VJ. (2006) Effects of pefloxacin in multi drug resistant typhoid fever. *Pak J Pharm Sci*, 19, 85.
14. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H. (2006) Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. *Lancet*, 368, 466.

15. Ignatova A, Dubiley S, Stepanshina V, Shemyakin I. (2006) Predominance of multi-drug-resistant LAM and Beijing family strains among *Mycobacterium tuberculosis* isolates recovered from prison inmates in Tula Region, Russia. *J Med Microbiol*, 55, 1413.
16. Irfan S, Hassan Q, Hasan R. (2006) Assessment of resistance in multi drug resistant tuberculosis patients. *J Pak Med Assoc*, 56, 397.
17. Jin JS, Sakaeda T, Kakimoto M, Nishiguchi K, Nakamura T, Okamura N, Okumura K. (2006) Effect of therapeutic moderate hypothermia on multi-drug resistance protein 1-mediated transepithelial transport of drugs. *Neurol Med Chir (Tokyo)*, 46, 321.
18. Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA, Yoon SN, Chang HJ, Yoo BC, Park JG. (2006) Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. *Cancer Lett*.
19. Kannan S. (2006) Therapeutic significance of ectophosphatase inhibitors in reversal of multi-drug resistance. *Med Hypotheses*, 66, 1041.
20. Keller G, Schally AV, Nagy A, Baker B, Halmos G, Engel JB. (2006) Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. *Int J Oncol*, 28, 1507.
21. Kim DH, Lee NY, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. (2006) Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia. *Leuk Lymphoma*, 47, 461.
22. Laloo UG, Naidoo R, Ambaram A. (2006) Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. *Curr Opin Pulm Med*, 12, 179.
23. Layten M, Hornak V, Simmerling C. (2006) The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts. *J Am Chem Soc*, 128, 13360.
24. Li GH, Wang M, Sun FJ, Wang XR, Li XJ, Yin GP. (2006) [Study of matrine's use on the reversion of obtained multi-drug resistance of mice S80 tumour cell]. *Zhong Yao Cai*, 29, 40.
25. Li WT, Jiang GN, Gao W, Xiao HP, Ding JA. (2006) [Surgical treatment of multi-drug resistant pulmonary tuberculosis in 188 cases]. *Zhonghua Jie He He Hu Xi Za Zhi*, 29, 524.
26. Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA. (2006) Clinical Prediction Tool to Identify Patients with *Pseudomonas aeruginosa* Respiratory Tract Infections at Greatest Risk for Multi-Drug Resistance. *Antimicrob Agents Chemother*.
27. Lou JY, Peng ZL, Zheng Y, Wang H, He B, Wang HJ. (2006) [Reversal of multi-drug resistance in ovarian cancer cell by RNA interference]. *Zhonghua Fu Chan Ke Za Zhi*, 41, 413.
28. Matsunaga S, Asano T, Tsutsuda-Asano A, Fukunaga Y. (2006) Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). *Cancer Chemother Pharmacol*, 58, 348.
29. Musto J, Kirk M, Lightfoot D, Combs BG, Mwanri L. (2006) Multi-drug resistant *Salmonella* Java infections acquired from tropical fish aquariums, Australia, 2003-04. *Commun Dis Intell*, 30, 222.
30. Nakajima H, Mizuta N, Mizuta M, Nakatsukasa K, Kobayashi A, Hachimine Y, Sakaguchi K, Fujiwara I, Sawai K. (2006) [A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab]. *Gan To Kagaku Ryoho*, 33, 1305.
31. Ode H, Neya S, Hata M, Sugiura W, Hoshino T. (2006) Computational simulations of HIV-1 proteases-multi-drug resistance due to nonactive site mutation L90M. *J Am Chem Soc*, 128, 7887.
32. Ogeer-Gyles J, Mathews K, Weese JS, Prescott JF, Boerlin P. (2006) Evaluation of catheter-associated urinary tract infections and multi-drug-resistant *Escherichia coli* isolates from the urine of dogs with indwelling urinary catheters. *J Am Vet Med Assoc*, 229, 1584.
33. Olle-Goig JE. (2006) Editorial: the treatment of multi-drug resistant tuberculosis--a return to the pre-antibiotic era? *Trop Med Int Health*, 11, 1625.

34. Palomino JC. (2006) Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. *Curr Opin Pulm Med*, 12, 172.
35. Pitts LH. (2006) Supplementary comment on "Effect of therapeutic moderate hypothermia on multi-drug resistance protein 1-mediated transepithelial transport of drugs". *Neurol Med Chir (Tokyo)*, 46, 418.
36. Piwnica-Worms D, Kesarwala AH, Pichler A, Prior JL, Sharma V. (2006) Single Photon Emission Computed Tomography and Positron Emission Tomography Imaging of Multi-drug Resistant P-glycoprotein-Monitoring a Transport Activity Important in Cancer, Blood-Brain Barrier Function and Alzheimer's Disease. *Neuroimaging Clin N Am*, 16, 575.
37. Price MJ, Giap H, Teirstein PS. (2006) Intracoronary radiation therapy for multi-drug resistant in-stent restenosis: Initial clinical experience. *Catheter Cardiovasc Interv*.
38. Quinn T, O'Mahony R, Baird AW, Drudy D, Whyte P, Fanning S. (2006) Multi-drug resistance in *Salmonella enterica*: efflux mechanisms and their relationships with the development of chromosomal resistance gene clusters. *Curr Drug Targets*, 7, 849.
39. Rosenwald A. (2006) Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): A feature of B-CLL sub-sets with poor prognosis genetic alterations? *Leuk Lymphoma*, 47, 2263.
40. Saidani M, Boutiba I, Ghazzi R, Kammoun A, Ben Redjeb S. (2006) [Bacteriologic profile of bacteremia due to multi-drug resistant bacteria at Charles-Nicolle Hospital of Tunis]. *Med Mal Infect*, 36, 163.
41. Scott GM, Weinberg A, Rawlinson WD, Chou S. (2006) Multi-Drug Resistance Conferred by Novel DNA Polymerase Mutations in Human Cytomegalovirus Isolates. *Antimicrob Agents Chemother*.
42. Sekiguchi JI, Miyoshi-Akiyama T, Augustynowicz-Kopec E, Zwolska Z, Kirikae F, Toyota E, Kobayashi I, Morita K, Kudo K, Kato S, Kuratsujii T, Mori T, Kirikae T. (2006) Detection of Multi-Drug Resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol*.
43. Sharma SK, Farah D, Misra-Bhattacharya S, Bajpai P, Agarwal A, Mohammad O. (2006) Escheriosome entrapped soluble blood stage antigens impart protective immunity against a multi-drug resistant isolate of *Plasmodium yoelii nigeriensis* in BALB/c mice. *Vaccine*, 24, 948.
44. Shi YJ, Ren HY, Cen XN, Zhu Q, Yu JR. (2006) [Immunological effector cells enhance apoptosis induced by adriamycin in a multi-drug resistant human breast cancer cell line]. *Zhonghua Zhong Liu Za Zhi*, 28, 188.
45. Shi YJ, Ren HY, Cen XN, Zhu Q, Yu JR. (2006) [Immunological effector cells enhance apoptosis induced by adriamycin in a multi-drug resistant human breast cancer cell line]. *Zhonghua Zhong Liu Za Zhi*, 28, 188.
46. Singh C, Malik H, Puri SK. (2006) Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylviny)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant *plasmodium yoelii nigeriensis* in mice. *J Med Chem*, 49, 2794.
47. Takebe Y, Teleshnitsky A. (2006) Evidence for the acquisition of multi-drug resistance in an HIV-1 clinical isolate via human sequence transduction. *Virology*, 351, 1.
48. Tanaka Y, Tsujimura S. (2006) [Multi-drug resistance in the treatments of autoimmune diseases]. *Nihon Rinsho Meneki Gakkai Kaishi*, 29, 319.
49. Tang SJ. (2006) [Advances in the study of drugs for the treatment of multi-drug resistant tuberculosis]. *Zhonghua Jie He He Hu Xi Za Zhi*, 29, 567.
50. Thwaites GE, Hien TT, Farrar JJ. (2006) Reply to "Dr D Dhasmana and Dr R Davidson: Multi-drug resistant tuberculous meningitis". *J Infect*.
51. Tomasoni D, Gattuso G, Chiarelli C, Palvarini L, Ceruti R, Berra D, Stradoni R, Scalzini A. (2006) [Epidemiologic surveillance of multi-drug resistant *Pseudomonas aeruginosa* in Mantova Hospital (Italy)]. *Infez Med*, 14, 85.
52. Tu DH. (2006) [Establishing DOTS-Plus strategy for control of multi-drug resistant tuberculosis]. *Zhonghua Jie He He Hu Xi Za Zhi*, 29, 507.
53. Vincent M. (2006) Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. *Med Hypotheses*, 66, 715.

54. Vonberg RP, Wolter A, Ziesing S, Gastmeier P. (2006) Surveillance of cystic fibrosis patients with multi-drug resistant Gram-negative rods. *Int J Hyg Environ Health*, 209, 333.
55. Wensing AM, Boucher CA, van Kasteren M, van Dijken PJ, Geelen SP, Juttmann JR. (2006) Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. *Aids*, 20, 1465.
56. Yang L, Han LZ, Sun JY, Yu YS, Ni YX. (2006) [Molecular epidemiological study of colistin-only-sensitive strains of multi-drug resistant *Acinetobacter baumannii*]. *Zhonghua Yi Xue Za Zhi*, 86, 592.
57. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. (2006) Evolution of multi-drug resistant hepatitis B virus during sequential therapy. *Hepatology*, 44, 703.
58. Yu HQ, Ji CY, Ma DX, Zang SL. (2006) [Reversal of multi-drug resistance in K562/A02 cells by two short hairpin RNAs (shRNA) of mdr1]. *Zhonghua Xue Ye Xue Za Zhi*, 27, 456.
59. Zaborina O, Kohler JE, Wang Y, Bethel C, Shevchenko O, Wu L, Turner JR, Alverdy JC. (2006) Identification of multi-drug resistant *Pseudomonas aeruginosa* clinical isolates that are highly disruptive to the intestinal epithelial barrier. *Ann Clin Microbiol Antimicrob*, 5, 14.
60. Zhu LZ, Fu Y, Chu NH, Ye ZZ, Xiao HP, Wang W, Yuan SL, Zhang X, Luo YA, Ma LP. (2006) [A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis]. *Zhonghua Jie He He Hu Xi Za Zhi*, 29, 520.
61. Fekete MR, McBride WH, Pajonk F. (2005) Anthracyclines, proteasome activity and multi-drug-resistance. *BMC Cancer*, 5, 114.
62. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J, Cinatl J, Jr. (2005) Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. *Int J Oncol*, 27, 1029.
63. Xu XP, Fei XH, Chen L, Lu SQ, Gao L, Ni X, Xu XW, Jia XY. (2005) [Establishment of a mouse model for detecting multi-drug resistant minimal residual leukemia cells expressing green fluorescent protein]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*, 13, 1014.
64. Nissler L, Gebhardt R, Berger S. (2004) Flavonoid binding to a multi-drug-resistance transporter protein: an STD-NMR study. *Anal Bioanal Chem*, 379, 1045.
65. Han Y, Shi Y, Zhang H. (2001) [Alteration of subcellular distribution of protein kinase C isoforms in swelling-activated multi-drug-resistant gastric cancer cells and its significance]. *Zhonghua Yi Xue Za Zhi*, 81, 328.
66. Heike Y, Kasuno K, Kunisaki C, Hama S, Saito N, Tsuruo T, Kuntz DA, Rose DR, Curie DT. (2001) Overcoming multi-drug resistance using an intracellular anti-MDR1 sFv. *Int J Cancer*, 92, 115.
67. Lamy T, Drenou B, Grulio I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R, et al. (1995) Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. *Leukemia*, 9, 1549.
68. Ling YH, Zou Y, Priebe W, Perez-Soler R. (1995) Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. *Int J Cancer*, 61, 402.
69. Wadkins RM, Houghton PJ. (1993) The role of drug-lipid interactions in the biological activity of modulators of multi-drug resistance. *Biochim Biophys Acta*, 1153, 225.
70. Callaghan R, van Gorkom LC, Epand RM. (1992) A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. *Br J Cancer*, 66, 781.
71. Kessel D, Erickson C. (1992) Porphyrin photosensitization of multi-drug resistant cell types. *Photochem Photobiol*, 55, 397.
72. Lahmy S, Salmon JM, Vigo J, Viallet P. (1992) Identification of multi-drug resistant cells in sensitive Friend leukemia cells by quantitative videomicrofluorimetry. *Cell Biochem Funct*, 10, 9.
73. Takeda Y, Nishio K, Sugimoto Y, Kasahara K, Kubo S, Fujiwara Y, Niitani H, Saito N. (1991) Establishment of a human leukemia subline resistant to the growth-inhibitory

- effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance. *Int J Cancer*, 48, 931.
74. van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C, Vellenga E, Mulder PO, Mulder NH. (1991) In vitro and in vivo modulation of multi-drug resistance with amiodarone. *Int J Cancer*, 48, 616.
75. Larsson R, Nygren P. (1990) Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. *Int J Cancer*, 46, 67.
76. Smith PJ, Morgan SA, Fox ME, Watson JV. (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. *Biochem Pharmacol*, 40, 2069.
77. Morgan SA, Watson JV, Twentyman PR, Smith PJ. (1989) Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer. *Br J Cancer*, 60, 282.
78. Supino R, Mariani M, Capranico G, Colombo A, Parmiani G. (1988) Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. *Br J Cancer*, 57, 142.
79. Brox A, Price G, Sullivan AK. (1985) An antigen related to the phenotype of multi-drug resistance can be induced in vivo and used as a target for immunotherapy of rat leukemia. *Leuk Res*, 9, 987.